ERBB2 and neoplasm: Moreover, it has been reported that such alterations provide prognostic information with loss of HER2-positivity in residual tumours after neoadjuvant treatment shown to be associated with a poorer outcome compared with tumours with preserved HER2-positive status [16–18].